NCT03210519

To Evaluate the Efficacy of Eleutherococcus Senticosus for Subjects Under Renal Dialysis

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Eleutherococcus Senticosus for Anti-inflammation and Improvement of Erythropoietin Hyporesponsiveness in Subjects Under Renal Dialysis

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Chung Shan Medical University · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, placebo-controlled, parallel comparison trial to evaluate the efficacy and safety of Eleutherococcus Senticosus taken orally by patients under regular dialysis. Eligible subjects with written consent were randomized into one of the two groups: A. Acanthopanax senticosus (30mg/vial); B. Placebo. After 2-4 weeks of run-in period, the study subjects were asked to take the investigational products orally for 90 days in order to evaluate the effects of oral Eleutherococcus Senticosus liquid on the markers of inflammation, anemia, and safety, and to compare the efficacy among oral Acanthopanax senticosus and placebo.

Conditions

• Renal Dialysis

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Eleutherococcus senticosus	taken orally once/day for 90 days
OTHER	Placebo	taken orally once/day for 90 days

Timeline

• Start date: 2015-12-09
• Primary completion: 2017-06-30
• Completion: 2017-06-30
• First posted: 2017-07-07
• Last updated: 2020-09-16
• Results posted: 2020-05-06